EMA (EU)
GUIDANCE FINAL
Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of hypertension (EMA/CHMP/29947/2013/Rev.4)
Published: 10/19/2026Detected: 10/19/2026
Summary preview
Initiates a revision of the EMA/CHMP guideline on clinical investigation of medicinal products for hypertension, reflecting evolving scientific consensus on hypertension definitions and treatment strategies (including…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountcardiology
clinical
safety
labeling
quality
#hypertension
#clinical investigation
#blood pressure targets
#trial design
#endpoints
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course - October 202610/26/2026
- Fifth European Medicines Agency (EMA) - Vaccines Europe bilateral meeting10/26/2026
- Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system10/26/2026
- Pharmacovigilance Risk Assessment Committee (PRAC): 26 - 29 October 202610/26/2026
- European platform for regulatory science research meeting: October 202610/22/2026